MA46098A - Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r - Google Patents

Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r

Info

Publication number
MA46098A
MA46098A MA046098A MA46098A MA46098A MA 46098 A MA46098 A MA 46098A MA 046098 A MA046098 A MA 046098A MA 46098 A MA46098 A MA 46098A MA 46098 A MA46098 A MA 46098A
Authority
MA
Morocco
Prior art keywords
antagonist
giving
preventing
methods
treating allergy
Prior art date
Application number
MA046098A
Other languages
English (en)
Inventor
Jennifer D Hamilton
Brian N Swanson
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA46098A publication Critical patent/MA46098A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
MA046098A 2016-09-01 2017-08-31 Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r MA46098A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382501P 2016-09-01 2016-09-01
US201662425726P 2016-11-23 2016-11-23

Publications (1)

Publication Number Publication Date
MA46098A true MA46098A (fr) 2019-07-10

Family

ID=59923551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046098A MA46098A (fr) 2016-09-01 2017-08-31 Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r

Country Status (9)

Country Link
US (2) US11771743B2 (fr)
EP (1) EP3506931B1 (fr)
JP (2) JP2019531273A (fr)
KR (3) KR20220151021A (fr)
CN (2) CN109789196B (fr)
CA (1) CA3035202A1 (fr)
MA (1) MA46098A (fr)
MX (2) MX2019002344A (fr)
WO (1) WO2018045130A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
IL303337A (en) 2014-11-14 2023-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR20220151021A (ko) 2016-09-01 2022-11-11 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
AU2018359219A1 (en) 2017-10-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CA3119090A1 (fr) * 2018-11-07 2020-05-14 Seasun Therapeutics Composition pour la prevention ou le traitement de la dermatite atopique comprenant un complexe d'acide nucleique penetrant dans la peau en tant que principe actif
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
WO2021119028A1 (fr) 2019-12-09 2021-06-17 Sanofi Biotechnology Méthodesde traitement de troubles associés à l'il-4/il-13 identifiés numériquement
EP3992974A1 (fr) 2020-11-02 2022-05-04 Sanofi Biotechnology Procédés pour le traitement de troubles liés à l'il-13/il-4 identifiés numériquement
KR20230130681A (ko) * 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
CN114805572B (zh) * 2021-01-22 2022-12-13 上海济煜医药科技有限公司 抗原结合蛋白及其应用
KR20230111729A (ko) 2022-01-19 2023-07-26 연세대학교 원주산학협력단 단삼 추출물을 유효성분으로 포함하는 알레르기 질환 예방 또는 치료용 조성물
WO2023208104A1 (fr) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 Anticorps anti-ra de l'il-4 humaine et son application

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH06510750A (ja) 1991-05-03 1994-12-01 セラジェン　インク 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (fr) 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
EP1113818B1 (fr) 1998-09-18 2006-05-17 Dynavax Technologies Corporation PROCEDES DE TRAITEMENT DE TROUBLES ASSOCIES A IgE ET COMPOSITIONS POUVANT ETRE UTILISEES A CET EFFET
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP3190126A1 (fr) 2000-05-26 2017-07-12 Immunex Corporation Utilisation d'anticorps contre le recepteur d'interleukine-4 (il-4r) et compositions correspondantes
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
IL156276A0 (en) 2000-12-22 2004-01-04 Nestle Sa Induction of tolerance
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
CA2446108A1 (fr) 2001-05-11 2002-11-21 Novartis Ag Compositions permettant de traiter les troubles associes aux ige
WO2002093998A2 (fr) 2001-05-23 2002-11-28 Duotol Ab Suppression de reactions allergiques par administration intradermique d'allergenes conjugues avec des sous unites de toxine ou des fragments de celle-ci
ATE517855T1 (de) 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2004047793A1 (fr) 2002-11-26 2004-06-10 Alk-Abelló A/S Produit pharmaceutique comprenant des allergenes
EP1592776A4 (fr) 2003-02-01 2008-06-04 Tanox Inc Anticorps ige anti-humains a affinite elevee
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2005063817A2 (fr) 2003-12-22 2005-07-14 Amgen Inc. Procédés d'identification d'anticorps fonctionnels
CA2554596A1 (fr) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
EP2301969B1 (fr) 2005-05-06 2015-12-23 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
MY147468A (en) 2006-06-02 2012-12-14 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR101555068B1 (ko) 2007-03-22 2015-10-06 제넨테크, 인크. 막 결합형 ｉｇｅ에 결합하는 세포자멸성 항-ｉｇｅ 항체
EP2022507A1 (fr) 2007-08-07 2009-02-11 Universität Hamburg Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010065557A2 (fr) 2008-12-01 2010-06-10 Cincinnati Children's Hospital Medical Center Procédés de détermination de l'efficacité d'un traitement par glucocorticoïde de l'oesophagite à éosinophiles
WO2010120524A2 (fr) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Procédés de modulation d'une réponse immunitaire à une infection virale
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
JP5879265B2 (ja) 2009-09-07 2016-03-08 デベヴェ・テクノロジーズ 好酸球性食道炎を処置する方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP3970726A1 (fr) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Procédés de traitement de l'inflammation de l' sophage
EA028945B1 (ru) 2010-10-06 2018-01-31 Ридженерон Фармасьютикалз, Инк. СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
CA2824043A1 (fr) 2011-01-06 2012-07-12 Marc E. Rothenberg Profils d'expression de cytokine oesophagienne dans l'oesophagite a eosinophiles
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
WO2012177945A2 (fr) 2011-06-21 2012-12-27 Children's Hospital Medical Center Méthodes de diagnostic pour œsophagite à éosinophiles
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
WO2013088109A1 (fr) 2011-12-16 2013-06-20 Oxagen Limited Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l'œsophagite à éosinophiles
BR112014018471A2 (pt) 2012-01-31 2017-07-04 Genentech Inc anticorpos anti-ige m1' e métodos para o seu uso
WO2013155010A1 (fr) 2012-04-09 2013-10-17 Children's Hospital Medical Center Biomarqueurs non invasifs pour l'œsophagite éosinophile
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
LT2892927T (lt) 2012-09-07 2018-09-10 Regeneron Pharmaceuticals, Inc. Atopinio dermatito gydymo būdai, skiriant il-4r antagonistą
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
EP2953974B1 (fr) 2013-02-05 2017-12-20 EngMab Sàrl Anticorps bispécifiques contre cd3 et bcma
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
WO2014205365A1 (fr) 2013-06-21 2014-12-24 Sanofi Méthodes de traitement de la polypose nasale par administration d'un antagoniste d'il-4 r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP6673840B2 (ja) 2014-02-21 2020-03-25 サノフィ・バイオテクノロジー Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
IL303337A (en) 2014-11-14 2023-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
MX2018009990A (es) 2016-02-19 2018-12-17 Regeneron Pharma Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
KR20220151021A (ko) 2016-09-01 2022-11-11 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
AU2017332732B2 (en) 2016-09-22 2024-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CA3052779A1 (fr) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Traitements d'association pour le traitement de cancers associes a bcma et de troubles auto-immuns
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
AU2018359219A1 (en) 2017-10-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
EP4406975A2 (fr) 2018-06-14 2024-07-31 Ajinomoto Co., Inc. Composé ayant une substance d'affinité pour un anticorps et un groupe fonctionnel bioorthogonal, ou un sel de celui-ci
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
KR20220004708A (ko) 2019-05-01 2022-01-11 사노피 바이오테크놀로지 Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
WO2021119028A1 (fr) 2019-12-09 2021-06-17 Sanofi Biotechnology Méthodesde traitement de troubles associés à l'il-4/il-13 identifiés numériquement
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
BR112022022235A2 (pt) 2020-05-22 2023-03-28 Regeneron Pharma Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
KR20230130681A (ko) 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법

Also Published As

Publication number Publication date
CN118141914A (zh) 2024-06-07
KR20240065318A (ko) 2024-05-14
US20240082353A1 (en) 2024-03-14
CA3035202A1 (fr) 2018-03-08
CN109789196B (zh) 2024-03-19
EP3506931B1 (fr) 2024-07-31
JP2019531273A (ja) 2019-10-31
KR20190042702A (ko) 2019-04-24
MX2019002344A (es) 2019-09-06
KR20220151021A (ko) 2022-11-11
JP2022169718A (ja) 2022-11-09
US20190183973A1 (en) 2019-06-20
US11771743B2 (en) 2023-10-03
EP3506931A1 (fr) 2019-07-10
WO2018045130A1 (fr) 2018-03-08
MX2023004306A (es) 2023-05-04
CN109789196A (zh) 2019-05-21
KR102462039B1 (ko) 2022-11-02

Similar Documents

Publication Publication Date Title
MA46098A (fr) Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
MA45192A (fr) Traitement d'association
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA46954A (fr) Méthodes de traitement d'états inflammatoires
DK3698847T3 (da) Magnetisk stimuleringsudstyr til terapeutisk behandling
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
MA44234A (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
DK3393579T3 (da) Øjenbehandlingssystem
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MA42999A (fr) Polythérapie pour le traitement de malignités
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
DK3451886T3 (da) Gulvbehandlingssystem
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
MA51525A (fr) Traitement de minéraux
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee